Received Nov 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 35A77 | — |
Fairly significant amount of itching at site of injection; arm became red; Inflamed arm; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of injection site itching in a 62-year-old female patient who received Herpes zoster (Shingrix) (batch number 35A77, expiry date 04-APR-2027) for prophylaxis. On 14-OCT-2025, the patient received the 1st dose of Shingrix. On 14-OCT-2025, less than a day after receiving Shingrix, the patient experienced injection site itching (Verbatim: Fairly significant amount of itching at site of injection), erythema of extremities (Verbatim: arm became red) and inflammation localized (Verbatim: Inflamed arm). The outcome of the injection site itching, erythema of extremities and inflammation localized were resolved (duration 4 days). It was unknown if the reporter considered the injection site itching, erythema of extremities and inflammation localized to be related to Shingrix. It was unknown if the company considered the injection site itching, erythema of extremities and inflammation localized to be related to Shingrix. Additional Information: GSK Receipt Date: 13-NOV-2025 Pharmacist mentioned that a patient got first dose of Shingrix on October 14th 2025, and when she received the shot their arm became red and inflamed, and she experienced fairly significant itching at the site of injection, it kept her up at night, but it did resolved after 3 or 4 days. The Vaccine Administration Facility was the same as Primary Reporter.